Resmed Inc (RMD) Stock Price, Quote & News

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 858-836-5000

Website: www.resmed.com

Address:

9001 Spectrum Center Boulevard, San Diego, United States

IldijanaMM Feb. 9 at 1:46 PM

$RMD Aren’t you guys not worried about this company sone starting to do icecream machines instead of CPAPs When IXHLs IHL-42X entering the market after its fast track! Zero side effects and 83% reduction

1 · Reply

ZacksResearch Feb. 6 at 1:15 PM

$RMD beats earnings estimates — but what's driving growth? 🚀 Adjusted EPS rose 15.6% YoY to $2.81, exceeding the Zacks Consensus Estimate by 4.59%. Revenue also topped estimates, fueled by robust performance in Sleep and Breathing Health and Residential Care Software segments. Discover how RMD’s strategic expansions could impact future growth 👉 https://www.zacks.com/stock/news/2835645/rmd-stock-up-following-q2-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2835645-body-32256&ADID=SYND_STOCKTWITS_TWEET_2_2835645_BODY_32256

1 · Reply

ZacksResearch Feb. 6 at 12:15 PM

$RMD pops after Q2 — this wasn’t a fluke. 🚀 Q2 earnings and revenue both came in ahead of expectations, and margins expanded — a powerful combo that explains why the stock is moving higher. See what drove the beat and margin expansion 👉 https://www.zacks.com/stock/news/2835645/rmd-stock-up-following-q2-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2835645-teaser-32251&ADID=SYND_STOCKTWITS_TWEET_2_2835645_TEASER_32251

0 · Reply

InLongtoRetire Feb. 6 at 12:34 AM

$RMSL It’s a bloodbath out there but $RMSL and $RMD are holding their own. May be time to jump back into Tesla and Amazon.

1 · Reply

Chapman211 Feb. 5 at 7:46 PM

$IXHL damn. In a market that’s bleeding $RMD is still climbing. Hard to look at our pps

1 · Reply

BritCharts Feb. 4 at 6:51 PM

$RMD Quiet accumulation, under the radar, could breakout above key level

0 · Reply

Any_real_help_here Feb. 4 at 4:04 PM

$RMSL $IBRX $TNXP $RMD In early 2026, REMSleep Holdings, Inc. (RMSL) announced major milestones for its DeltaWave™ nasal pillow system, including receiving Medicare PDAC coding approval and expanded FDA 510(k) clearance in January. These approvals enable a nationwide full commercial launch for home and institutional use, marking a critical step toward commercialization. Contracts coming, large and small.......

1 · Reply

Rvvrn9 Feb. 4 at 12:01 PM

$IXHL $RMD Correct and that vehicle will continue operating under $RMD umbrella as their pharmaceutical arm through Ihl-42X P3 completion as well as secondary assets. The vehicle continues in motion, nothing changes except the sign on the door.

1 · Reply

Rvvrn9 Feb. 4 at 11:44 AM

$IXHL $RMD Too late my friend

1 · Reply

Ernesto62 Feb. 4 at 11:42 AM

$IXHL $RMD stop this bullshit

0 · Reply

Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

NVO

Feb 1, 2026, 12:54 AM EST - 11 days ago

ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell

Jan 30, 2026, 1:08 PM EST - 12 days ago

Analysts Maintain Bull Case On ResMed Despite Competition Concerns

Jan 29, 2026, 8:23 PM EST - 13 days ago

ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript

Jan 29, 2026, 4:41 PM EST - 13 days ago

ResMed beats quarterly profit estimates on strong demand for its sleep devices

Jan 29, 2026, 4:05 PM EST - 13 days ago

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Jan 12, 2026, 6:56 PM EST - 4 weeks ago

ResMed Inc. (RMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 4:05 PM EST - 4 weeks ago

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

Dec 18, 2025, 4:05 PM EST - 7 weeks ago

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 9:03 PM EST - 2 months ago

Top 50 High-Quality Dividend Growth Stocks For December 2025

ACN ALLE APH DHI DPZ FDS GGG

Dec 8, 2025, 9:00 AM EST - 2 months ago

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

Nov 24, 2025, 2:15 PM EST - 2 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX

Nov 17, 2025, 5:24 PM EST - 3 months ago

ResMed: Safe Bet For A Recession Environment

Oct 31, 2025, 9:24 AM EDT - 3 months ago

These Analysts Revise Their Forecasts On ResMed Following Q1 Results

Oct 30, 2025, 10:16 PM EDT - 3 months ago

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

Oct 30, 2025, 4:05 PM EDT - 3 months ago

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

Oct 9, 2025, 4:05 PM EDT - 4 months ago

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

Oct 3, 2025, 10:46 AM EDT - 4 months ago

Top 50 High-Quality Dividend Growth Stocks For October 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Sep 23, 2025, 11:53 AM EDT - 5 months ago

ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 16, 2025, 4:05 PM EDT - 5 months ago

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

Sep 8, 2025, 9:00 PM EDT - 5 months ago

The sleep economy is 'having a moment', says medical equipment firm Resmed

Sep 6, 2025, 12:18 PM EDT - 5 months ago

Top 50 High-Quality Dividend Stocks For September 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Sep 3, 2025, 4:15 PM EDT - 5 months ago

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Aug 27, 2025, 9:00 AM EDT - 6 months ago

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

Aug 27, 2025, 7:43 AM EDT - 6 months ago

ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows

Aug 18, 2025, 4:15 PM EDT - 6 months ago

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

Aug 6, 2025, 11:50 AM EDT - 6 months ago

Top 50 High-Quality Dividend Stocks For August 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Aug 1, 2025, 2:16 PM EDT - 6 months ago

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Jul 31, 2025, 9:39 PM EDT - 6 months ago

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

Jul 31, 2025, 4:53 PM EDT - 6 months ago

Resmed beats quarterly profit estimates on strong demand for sleep devices

Jul 31, 2025, 4:05 PM EDT - 6 months ago

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Jul 30, 2025, 6:08 AM EDT - 7 months ago

Spot Outliers Like ResMed Early with Money Flows

Jul 1, 2025, 9:02 PM EDT - 8 months ago

Top 15 High-Growth Dividend Stocks For July 2025

APH BAC BK DKS DPZ ELV GPN

Jul 1, 2025, 4:05 PM EDT - 8 months ago

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Jun 9, 2025, 5:38 AM EDT - 8 months ago

ResMed: A Sleeping Giant Hiding In Plain Sight

Jun 2, 2025, 10:00 AM EDT - 9 months ago

Top 15 High-Growth Dividend Stocks For June 2025

DKS DPZ GPN INTU KLAC LRCX MPWR

May 15, 2025, 9:00 AM EDT - 9 months ago

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

May 2, 2025, 11:21 AM EDT - 10 months ago

Top 15 High-Growth Dividend Stocks To Consider For May 2025

AMAT APH DKS DPZ GPN INTU LRCX

May 1, 2025, 9:00 AM EDT - 10 months ago

Resmed Acquires VirtuOx

Apr 24, 2025, 3:24 PM EDT - 10 months ago

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

Apr 24, 2025, 5:12 AM EDT - 10 months ago

ResMed: Cornering The Market In Sleep Solutions

Apr 23, 2025, 7:16 PM EDT - 10 months ago

ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript

Apr 23, 2025, 5:08 PM EDT - 10 months ago

ResMed slightly beats quarterly profit estimates on sleep devices demand

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Apr 21, 2025, 5:00 PM EDT - 10 months ago

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Apr 3, 2025, 9:00 AM EDT - 11 months ago

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Apr 2, 2025, 4:05 PM EDT - 11 months ago

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Apr 2, 2025, 2:12 AM EDT - 11 months ago

My Top 15 High-Growth Dividend Stocks For April 2025

AMAT APH DPZ GPN INTU LRCX MPWR

Mar 19, 2025, 8:00 AM EDT - 11 months ago

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

IldijanaMM Feb. 9 at 1:46 PM

1 · Reply

ZacksResearch Feb. 6 at 1:15 PM

1 · Reply

ZacksResearch Feb. 6 at 12:15 PM

0 · Reply

InLongtoRetire Feb. 6 at 12:34 AM

$RMSL It’s a bloodbath out there but $RMSL and $RMD are holding their own. May be time to jump back into Tesla and Amazon.

1 · Reply

Chapman211 Feb. 5 at 7:46 PM

$IXHL damn. In a market that’s bleeding $RMD is still climbing. Hard to look at our pps

1 · Reply

BritCharts Feb. 4 at 6:51 PM

$RMD Quiet accumulation, under the radar, could breakout above key level

0 · Reply

Any_real_help_here Feb. 4 at 4:04 PM

1 · Reply

Rvvrn9 Feb. 4 at 12:01 PM

1 · Reply

Rvvrn9 Feb. 4 at 11:44 AM

$IXHL $RMD Too late my friend

1 · Reply

Ernesto62 Feb. 4 at 11:42 AM

$IXHL $RMD stop this bullshit

0 · Reply

Rvvrn9 Feb. 4 at 11:35 AM

$IXHL + $RMD ….the timing and fit line up perfectly Incannex has taken IHL-42X as far as it needs to go to prove value. Phase 2 de-risked, Phase 3 urgent, and funding with RS and further dilution was never part of Joel’s plan. ResMed doesn’t have a pharma arm, but OSA is their core business. Acquiring IXHL skips years of development, blocks competitors, and drops a differentiated pill straight into their ecosystem

1 · Reply

WavefrontCapital Feb. 4 at 11:29 AM

$RMD is the CPAP leader navigating a major product recall; market share recapture and new product launches are critical.

0 · Reply

Rvvrn9 Feb. 4 at 11:28 AM

$IXHL $RMD

0 · Reply

Rvvrn9 Feb. 4 at 11:27 AM

$IXHL $RMD

0 · Reply

Rvvrn9 Feb. 4 at 11:24 AM

$IXHL $RMD

0 · Reply

Rvvrn9 Feb. 4 at 11:23 AM

$IXHL $RMD

0 · Reply

Rvvrn9 Feb. 4 at 11:19 AM

$IXHL $RMD

0 · Reply

BillionerOfKing Feb. 2 at 5:19 PM

$RMD Current Stock Price: $251.96 Contracts to trade: $250.0 RMD Feb 20 2026 Call Entry: $6.40 Exit: $11.60 ROI: 81% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

erevnon Jan. 30 at 3:16 PM

Stifel maintains ResMed $RMD at Hold and raises the price target from $260 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

InLongtoRetire Jan. 30 at 1:47 PM

$RMD

0 · Reply

stockro1 Jan. 30 at 6:52 AM

$IXHL I listened to the $RMD earbings call last night and it just continued to reinforced the amazing potential Incannex has for OSA. As much as it is impressive building hardware to fix the issue, medication is undoubtedly the way forward for the masses. The convenience and the barrier to entry is so much more favourable for Incannex vs needing to wear a headset whilst sleeping. There could be a future where both exist i.e. thoughts maybe Resmed for for serious conditions and Incannex more general population. However, the unequivocal fact is that, if done right and given the growing insight and science into the consequences of OSA, Incannex could have a really a once in a generation drug in its portfolio with IHL-42X that any big pharmaceutical company would want to have. And that’s without even mentioning PSX-001.

0 · Reply

howardlindzon Jan. 30 at 5:11 AM

$RMD sleep perking...

0 · Reply

Market Cap	38.39B
Revenue (ttm)	5.15B
Net Income (ttm)	1.40B
EPS (ttm)	N/A
PE Ratio	26.84
Forward PE	25.16
Profit Margin	27.22%
Debt to Equity Ratio	0.06

Volume	1,179,100
Avg Vol	1,054,390
Day's Range	N/A - N/A
Shares Out	145.68M
Stochastic %K	44%
Beta	0.87
Analysts	Sell
Price Target	$295.92